In June 2009, a technical consultation held at the World Health Organization (WHO) in Geneva concluded that evidence supports the introduction, continuation and scale-up of community-based provision of progestin-only injectable contraceptives. The group of 30 technical and program experts reviewed scientific and programmatic experience, which largely focused on the progestin-only injectable depot-medroxyprogesterone acetate (DMPA). The experts found that community-based provision of progestin-only injectable contraceptives by appropriately trained community health workers (CHWs) is safe, effective and acceptable. Such services should be part of a family planning program offering a range of contraceptive methods.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Medical eligibility criteria for contraceptive use.WHO, Geneva2004 (Updated 2008. Available from:)
- Current methods of the US Preventive Services Task Force: a review of the process.Am J Prev Med. 2001; 20: 21-35
- WHO-UNICEF-UNFPA Joint statement on the use of auto-disable syringes in immunization services.WHO, Geneva2003 (Available from:)
- United Nations Development Programme. Millennium development goals.(Available at)(accessed October 12, 2009)
Published online: December 03, 2009
Accepted: October 12, 2009
Received: October 7, 2009
���For more information on the consultation, including background papers and the evidence review, please go to: http://www.fhi.org/en/research/projects/progress/gtl/concba2i.htm.
© 2010 Published by Elsevier Inc.